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The study’s purpose was to investigate thyroid cancer incidence time trends, birth cohort eﬀects, and association with socio-
economic status (SES) in New Jersey (NJ), a high incidence state, using NJ State Cancer Registry data. Thyroid cancer incidence
rates in each sex, nearly all age groups, two major histologies and all stages signiﬁcantly increased between 1979 and 2006. For
each sex, age-speciﬁc incidence rates began greatly increasing in the 1924 birth cohort and, generally, the highest thyroid cancer
incidence rate for each ﬁve-year age group occurred in the latest birth cohort and diagnosis period. Thyroid cancer incidence
rates were signiﬁcantly higher in NJ Census tracts with higher SES and in counties with a higher percentage of insured residents.
Theseresultssupportfurtherinvestigationintotherelationship betweenrisingthyroidcancerincidenceandincreasingpopulation
exposure to medical (including diagnostic) radiation, as well as widespread use of more sensitive diagnostic techniques.
1.Introduction
While U.S. incidence rates for many common cancers
decreasedorremainedstablebetween1975and2006,thyroid
cancer incidence increased over 125% [1]. For 2002–2006,
New Jersey’s (NJ) average annual age-adjusted rate was a
third higher than the U.S. rate (12.8 versus 9.6 per 100,000)
[1] and NJ ranked ﬁfth among 47 states in 2001–2005
thyroid cancer incidence [2]. Although considered relatively
uncommon,thyroidcancercurrentlyranksseventhincancer
incidence among U.S. and NJ women [1, 3].
The major risk factor for thyroid cancer is exposure to
ionizing radiation, usually in childhood, either externally
from therapeutic X-radiation [4, 5] or internally through
treatment with radioactive iodine (131I) and possibly
radioactive fallout (131I) from above-ground nuclear bomb
testing in Nevada in the 1950s [4, 6–8]. An association bet-
ween exposure to diagnostic X-radiation and thyroid cancer
has been found in several case-control studies [9]. Other risk
factors are a history of thyroid disease including nodules,
goiter, and hyperthyroidism, familial or genetic factors and
iodine deﬁciency or excess [4].
X-radiation treatment of children for benign conditions
of the head and neck in the 1920s through the 1950s resulted
in higher thyroid cancer incidence through the 1945 birth
cohort [4, 10–12]. Increases in thyroid cancer incidence also
are attributed to widespread use since the 1980s of more
sensitive diagnostic techniques such as ultrasonography
and ﬁne-needle aspiration [13, 14]. However, these two
factors do not fully explain the continuing large increases
in thyroid cancer incidence in the past three decades
[9, 15, 16].
Socioeconomic status (SES) is commonly believed to be
an important determinant of health status in individuals
and populations [17]. In the USA, low SES is associated
with higher incidence of many cancer types, for example,
lung, stomach, and cervical, while high SES is related to
greater breast cancer and melanoma incidence [17]. Some
studies have found positive associations between high levels
of income, education, or other SES indicators and thyroid
cancer [18–21], while other studies found a negative or
no association [22–24]. Two recent studies show a positive
correlation between health insurance coverage and thyroid
cancer incidence [18, 19].2 Journal of Environmental and Public Health
In recent years, U.S. researchers have used deprivation
indices developed from several census variables as measures
of SES, rather than single census variables such as income
or education. These indices are commonly developed using
data reduction techniques that condense a large number of
variables into a smaller number of components to more
accurately reﬂect the multidimensional character of commu-
nity socioeconomic position [25]. Deprivation indices have
been used to study the relationships between SES and cancer
incidence and stage at diagnosis [26–28].
The purpose of this study was to investigate thyroid
cancer incidence time trends and birth cohort eﬀects from
1979 to 2006 in New Jersey (NJ), a high incidence state.
We also investigated the relationship between thyroid cancer
incidence and SES, as deﬁned by a deprivation index and
insurance status.
2. Methods
The New Jersey State Cancer Registry (NJSCR) is the
population-based cancer incidence registry that serves the
state of NJ, with a diverse population of over 8.7 million
people. The NJSCR has participated in the Centers for Dis-
ease Control and Prevention’s National Program of Cancer
Registries since it began in 1994 and is a National Cancer
Institute (NCI) Surveillance, Epidemiology, and End Results
(SEERs)expansion registry. Reciprocalreporting agreements
aremaintainedwithDelaware,Florida,Maryland,NewYork,
North Carolina, and Pennsylvania. The NJSCR includes
patientdemographiccharacteristics(birthdate,age,sex,race,
ethnicity) and clinical information on each cancer diagnosis.
The primary site and histology of each case are coded to
the International Classiﬁcation of Diseases for Oncology
(ICD-O), third edition [29], and the stage at diagnosis is
codedaccordingtoSEERsummarystage[30,31].Eachcase’s
residential address at the time of diagnosis is geocoded and
assigned a county and census tract. The North American
Association of Central Cancer Registries awarded the Gold
Standard, the highest possible, to the NJSCR for quality and
completeness of 1995 through 2006 data.
2.1. Time Trends. Primary invasive thyroid cancer cases
(ICD-O-3 site code 73.9) diagnosed in NJ residents during
1979–2006 were included, except cases reported only by
death certiﬁcate or autopsy report. Directly age-adjusted
thyroid cancer incidence rates per 100,000 population by
year of diagnosis, sex, race, ethnicity, histology, stage at
diagnosis, tumor size, and age-speciﬁc rates were calculated
using 1979–2006 NJ population estimates from the National
Center for Health Statistics (based on U.S. Census Bureau
data) [32] and the 2000 U.S. Standard Population. The time
trends for the race category Asian and Paciﬁc Islanders were
not calculated due to low numbers. U.S. thyroid cancer
incidence rates by year of diagnosis and sex were calculated
with data from nine SEER registries using the same methods
as for NJ rates. All rates were calculated in NCI’s SEER∗Stat
software [33].
Joinpoint regression software from NCI [34]w a su s e dt o
calculate the average annual percent changes (AAPCs) in NJ
thyroid cancer incidence rates by sex, race, age, histology and
stage,andinU.S.ratesbysexduring1979–2006andthemost
recent ten years, 1997–2006. AAPCs also were calculated
by Hispanic ethnicity but only for 1997–2006, as accurate
data are not available before 1990. Statistical signiﬁcance of
the AAPCs was determined with 95% conﬁdence intervals.
AAPCs were not calculated by tumor size because the data
were incomplete before 1999 and the percentages of cancers
with unknown size were greater than 20% for 1999–2003.
The AAPC is a summary measure of a time trend over
a prespeciﬁed ﬁxed period, for example, 1979–2006, and
is computed as a weighted average of the annual percent
changes (APCs) from the best underlying Joinpoint regres-
sion model, with weights equal to the intervals (line seg-
ments) between joinpoints [35]. To obtain the best under-
lying Joinpoint regression model, the software identiﬁes
points (joinpoints), where the rate of change in trend data
(e.g., annual cancer incidence rates) signiﬁcantly increases or
decreases,andprovidesanestimatedAPCbetweeneachjoin-
point[36].Itstartswithzerojoinpointsandcontinuestoadd
joinpoints up to a set maximum until adding one more join-
point does not statistically signiﬁcantly improve the model.
2.2. Birth Cohort Analysis. For the birth cohort analysis,
thyroid cancer cases younger than 20 were excluded due to
the small number of cases, and cases aged 85 and older were
excluded because birth cohorts could not be assigned. Age-
speciﬁc incidence rates by ﬁve-year grouped diagnosis year
and nine-year overlapping birth cohort were calculated for
each sex using SEER∗Stat. The 13 age groups were 20–24,
25–29...80–84, and the six ﬁve-year diagnosis periods were
1979–83, 1984–88,...,2004–06. The last diagnosis period
includesonlythreeyearsas2006wasthelastyearofcomplete
data. Nine-year overlapping birth cohorts (except the last
b i rt hc o h o rtw a s7y e a r s )w e r ed e ri v edu s i n gC o h o rt= Period
− Age, yielding a total of 18 birth cohorts from 1895–1903 to
1980–1986 [37]. The cohorts are identiﬁed by the mid-year
of birth, for example, the 1900–1908 birth cohort is labeled
“1904”.
2.3. Socioeconomic Status (SES) and Health Insurance. The
relationship between NJ thyroid cancer incidence and SES
was examined for the ﬁve years (1998–2002) centered at
the year 2000, the most recent year with publicly available
U.S. Census data at the census tract level. Since the NJSCR
doesnotcollectindividualcaseinformationonSESmeasures
such as income or educational attainment, a standardized
deprivation index, similar to one used in other studies [26],
was developed with 2000 U.S. Census data for NJ using
principle component analysis [38] and SAS (SAS procedure
PRINCOMP [39], SAS statistical software, SAS Institute
Inc., Cary, NC). Of the 1,950 census tracts in NJ, 23 with
missing SES variables were excluded from the development
of the deprivation index. The ﬁrst component scores for
each census tract were calculated using eleven census
variables—percent families below the poverty line, median
household income, percent female—headed households,
percent adults with less than high school education, percentJournal of Environmental and Public Health 3
males and females in management jobs, percent males and
females in professional jobs, percent unemployment, percent
renters, and percent owner-occupied homes worth less than
$300,000. The 1,927 census tracts were grouped into SES
quartiles based on the deprivation index scores; the higher
the deprivation index score, the more deprived the tract.
Age-adjusted thyroid cancer incidence rates per 100,000
population by sex for each SES quartile were calculated using
U.S. Census Bureau 2000 population data [32] and the 2000
U.S. Standard Population. For the rate ratios, the highest SES
quartile was the referent for the other three; the signiﬁcance
level was set at P<0.05 [40]. The rates and rate ratios were
calculated in SEER∗Stat. This analysis was not done by race
because the multiple race categories in the 2000 Census were
notallocatedtosingleracecategoriesatthecensustractlevel.
Estimates by the U.S. Census Bureau of the percentage
of residents aged 0–64 covered by health insurance in 2005
and 2006 were averaged for each NJ county [41, 42]. County
thyroid cancer age-adjusted incidence rates among persons
0–64 were calculated for 2005 and 2006 in SEER∗Stat using
2005-2006NJpopulationestimatesfromtheNationalCenter
for Health Statistics (based on U.S. Census Bureau data) [32]
and the 2000 U.S. Standard Population. A Pearson correla-
tion coeﬃcient between the 21 county thyroid cancer inci-
dence rates and average health insurance percent coverage
weighted by county populations was calculated using SAS.
3. Results
3.1. Time Trends and Birth Cohorts. After exclusion of the
death certiﬁcate only (n = 116) and autopsy only (n = 45)
cases,15,576invasiveprimarythyroidcancercasesdiagnosed
between 1979 and 2006 were analyzed. More than 98% of
the included cases were histologically conﬁrmed. The annual
count ranged from 229 cases in 1981 to 1,316 cases in 2006.
Three-fourths of the cases were female, 86% white, 54%
younger than 50 at diagnosis, 76% papillary histology, and
63% diagnosed at the local stage.
Overall, NJ thyroid cancer AAPCs showed signiﬁcant
incidence rate increases between 1979 and 2006, accelerating
in the most recent ten years (Table 1). The 1979–2006 rate
increases were more prominent among NJ women than
men and were greatest for black women, followed by white
women, black men, and white men. Rates signiﬁcantly
increased in each age group except women 80–84, with
the steepest increases in both sexes combined 45–49 and
70–74 and women 35–39 and 70–74. The greatest increase
occurred in thyroid cancer of papillary histology, although
follicular thyroid cancer also signiﬁcantly increased. Thyroid
cancer diagnosed at the local, regional, and distant stages
signiﬁcantly increased, while unknown stage signiﬁcantly
decreased (note: these AAPCs should be interpreted with
cautionasthepercentageofunknownstagewasover10%for
most years 1979–1995). Female Hispanic rates signiﬁcantly
increased in 1997–2006, while male Hispanic rates did not.
From 1999 to 2006, incidence rates increased for each tumor
size except unknown size decreased: ≤1cm–1.4 to 4.6; 1.1–
2.0cm–1.6 to 4.1; 2.1–5.0cm–2.2 to 4.2; >5.0cm–0.5 to 0.7
(datanotshown).NJAAPCswerehigherthanU.S.AAPCsin
both time periods for total, males and females, for example,
1979–2006—5.4%, 4.9%, 6.0% versus 3.8%, 3.3%, 3.8%,
respectively (U.S. data not shown in Table 1).
Age-speciﬁc thyroid cancer incidence per 100,000 NJ
women greatly increased beginning with the two oldest age
groups in the 1924 birth cohort and continued to rise in
younger age groups, including the 20–24 age group, as well
as in the older age groups in subsequent birth cohorts
(Table 2(a), Figure 1(a)). Every age group experienced steep
rate increases with increasingly later birth cohorts and
diagnosis periods. The highest rates occurred among women
in the 45–49, 50–54, and 55–59 age groups from the 1959,
1954, and 1949 birth cohorts. Male age-speciﬁc thyroid
cancerincidenceper100,000alsoincreasedgreatlybeginning
with the two oldest age groups in the 1924 birth cohort
(Table 2(b),Figure 1(b)). Aswith women,foreachagegroup
the rates in the most recent two birth cohorts generally were
much higher than for the earlier birth cohorts, but the high-
estratesoccurredinoldermeninearliercohorts,aged65–69,
70–74, and 75–79 of the 1939, 1934, and 1929 birth cohorts.
3.2. Socioeconomic Status (SES) and Health Insurance. Of the
3,924 thyroid cancer cases included in the SES deprivation
index analysis, approximately 33% and 14% were in the
highest and lowest SES quartiles, respectively (Table 3). The
highest SES quartile had the highest thyroid cancer incidence
rate—10.6 per 100,000 population, and each subsequently
lower SES quartile had a lower rate—6.5 for the lowest SES
quartile. The rates for the two lowest SES quartiles were
signiﬁcantly lower than the rate in the highest SES quartile
(P<0.05) while there was no statistical diﬀerence between
the two highest SES quartiles; the same pattern held for each
sex.Althoughfemaleratesweremuchhigherthanmalerates,
the rate ratios were similar for the two sexes.
In NJ’s 21 counties, the average percent of residents
ages 0–64 with health insurance in 2005-2006 ranged
from 73% to 89% and the 2005-2006 age-adjusted thyroid
cancer incidence rate (n = 2,026) ranged from 8.6 to 16.7
per 100,000 population. There was a signiﬁcant positive
correlation between the counties’ percent health insurance
coverage and incidence rates (Pearson correlation coeﬃcient
=0.56,R2 = 0.32,P = 0,008).Thus,approximatelyathirdof
the variation in county thyroid cancer incidence rates can be
explained by the percent of residents with health insurance.
4. Discussion
4.1. Time Trends and Birth Cohorts. Thyroid cancer inci-
dence in NJ men and women increased substantially from
1979 to 2006, most notably in the past ten years. This time
trend mirrored that in the USA; however, NJ AAPCs and
incidence rates after 1999 were substantially higher than the
USA’s. Our birth cohort analysis showed that thyroid cancer
age-speciﬁc incidence rates began greatly increasing in the
oldest members of the 1924 birth cohort, generally with
the highest thyroid cancer incidence rate for each ﬁve-year
age group occurring in the latest birth cohort and diagnosis
period for which data were available.4 Journal of Environmental and Public Health
Table 1: Thyroid cancer incidence trends in New Jersey by sex, race, ethnicity, and age. Histology and stage, 1979–2006, N = 15,576a.
Cases
1979–2006
Rateb
1979–2006
AAPCc
1979–2006
AAPCc
1997–2006
Total 15,576 6.9 5.4∗ 10.3∗
Sex Male 3,899 3.7 4.9∗ 8.2∗
Female 11,677 9.9 6.0∗ 10.9∗
Race
Male
White 3,439 3.9 5.0∗ 8.4∗
Black 239 2.1 5.6∗ 5.6∗
APId 110d 4.5d — 12.5∗
Female
White 10,014 10.3 6.1∗ 10.0∗
Black 870 7.3 7.2∗ 11.4∗
APId 396d 13.7d — 10.5∗
Ethnicityd
Male Hispanicd 169d 3.8d —2 . 0
Non-Hispanicd 2,037d 5.6d —8 . 1 ∗
Female Hispanicd 753d 14.2d —7 . 4 ∗
Non-Hispanicd 6,213d 15.5d — 12.2∗
Age
0–19 362 0.6 3.6∗ 3.6∗
20–24 578 3.7 4.2∗ 4.2∗
25–29 989 6.0 5.2∗ 5.2∗
30–34 1,402 7.8 5.4∗ 9.0∗
35–39 1,651 9.2 5.7∗ 10.7∗
40–44 1,719 10.4 4.8∗ 8.2∗
45–49 1,699 11.7 6.3∗ 11.2∗
50–54 1,526 11.8 6.0∗ 9.7∗
55–59 1,393 12.1 6.1∗ 10.1∗
60–64 1,105 10.9 6.0∗ 9.4∗
65–69 1,039 11.8 5.6∗ 10.8∗
70–74 835 11.2 6.7∗ 6.7∗
75–79 703 12.2 4.8∗ 12.4∗
80–84 348 9.1 2.8∗ 10.5∗
85+ 227 7.4 2.6∗ 2.6∗
Female
0–19 283 0.9 3.4∗ 3.4∗
20–24 471 6.1 4.2∗ 4.2∗
25–29 811 9.8 5.8∗ 7.2∗
30–34 1,140 12.4 5.8∗ 9.3∗
35–39 1,315 14.5 7.5∗ 9.2∗
40–44 1,335 15.8 5.0∗ 8.6∗
45–49 1,291 17.3 6.3∗ 13.8
50–54 1,127 16.9 6.0∗ 11.0∗
55–59 960 16.0 6.2∗ 10.6∗
60–64 750 14.0 5.6∗ 9.1
65–69 698 14.3 5.9∗ 11.0∗
70–74 558 13.0 6.7∗ 6.7∗
75–79 507 14.4 4.9∗ 12.5∗
80–84 252 10.1 2.6 11.3∗
85+ 179 8.1 2.6∗ 2.6∗Journal of Environmental and Public Health 5
Table 1: Continued.
Cases
1979–2006
Rateb
1979–2006
AAPCc
1979–2006
AAPCc
1997–2006
Histologye
Papillary 11,803 5.2 6.7∗ 11.5∗
Follicular 2,312 1.0 3.1∗ 5.5∗
Other 1,461 0.6 0.4 0.4
Male
Papillary 2,817 2.7 6.1∗ 9.7∗
Follicular 619 0.6 3.0∗ 3.0∗
Other 463 0.5 0.1 0.1
Female
Papillary 8,986 7.7 7.1∗ 12.0∗
Follicular 1,693 1.4 3.8∗ 6.0∗
Other 998 0.8 0.5 0.5
Stagef
Local 9,775 4.35 6.1∗ 12.8∗
Regional 3,476 1.54 10.2∗ 9.9∗
Distant 876 0.39 7.2∗ 4.5∗
Unknown 1,449 0.64 3.6∗ −4.5∗
aData are from the New Jersey State Cancer Registry, New Jersey Department of Health and Senior Services, November 2008 analytic data ﬁle. All primary
invasive cases of thyroid cancer diagnosed between 1979 and 2006 are included except death certiﬁcate only (116) and autopsy only (45) cases.
bRates are age-adjusted to the 2000 U.S. Standard Population direct method, except rates by age, are age-speciﬁc. All rates are expressed as number of cases
per 100,000 population. Age-speciﬁc rates were not calculated for men due to small numbers.
cAAPC: Average Annual Percent Change, calculated from the National Cancer Institute’s Joinpoint software.
dAPI is Asian and Paciﬁc Islander; the API data are for 1997–2006 only. The ethnicity data are for 1997–2006 only, as complete ethnicity data are not available
before 1990. Race and ethnicity are not mutually exclusive; the white and black race categories include white and black Hispanics.
eICD-O-3 Codes for papillary are 8050, 8052, 8130, 8260, 8340–8344, 8350, 8450, 8452 and for follicular are 8290, 8330–8332, 8335.
fThe 1979–2006 AAPCs should be interpreted with caution as the percentage of unknown stage was over 10% for most years 1979–1995.
∗Statistically signiﬁcant: the 95% conﬁdence interval does not include 0.
Zheng et al. found that the increase in thyroid cancer
incidence in Connecticut between 1935 and 1992 occurred
in the 1915–1945 birth cohorts, with decreasing incidence
in subsequent cohorts [10]. The authors noted that these
results were consistent with the hypothesis that radiation
treatment in the 1920s–1950s of children with benign head
and neck conditions was largely responsible for the rise in
thyroid cancer incidence rates in birth cohorts up to 1945.
However, a more recent age-period-cohort modeling of U.S.
SEER papillary thyroid cancer data from 1973 through 2004
found a strong continuous birth cohort eﬀect, as well as a
period eﬀect [9]. The researchers concluded that the period
eﬀect, likely due to increased diagnosis of thyroid cancer,
explains some of the rise in thyroid cancer rates, and that
birth cohort-related increased exposure to environmental
factors such as diagnostic X-rays and hormone disrupters
(polybrominated diphenyl ethers, other polyhalogenated
aromatic hydrocarbons) also may have contributed. The
results of our birth cohort analysis are consistent with those
from the more recent study [9]. What could account for the
continuing increase in thyroid cancer incidence, speciﬁcally
in birth cohorts after 1944?
More sensitive diagnostic techniques for thyroid cancer,
widely used since the 1980s (ultrasound) and 1990s (ﬁne-
needle aspiration), increased the ability to diagnose very
small thyroid cancers that would have been missed previ-
ously [14]; however, recent research indicates that this does
not explain all the increase [9, 15, 16]. Tumors of all sizes
and stages have increased, not just small and early-stage
tumors, and thyroid cancer mortality rates have not changed
[9, 15, 16]. Also, no plateau in thyroid cancer incidence rates
has occurred, as expected after a temporary increase in rates
due to new, more sensitive diagnostic techniques becoming
widely used.
Assumingthatpartoftheriseinthyroidcancerincidence
rates reﬂects an actual increase in thyroid cancer, reasons
for the increase related to thyroid cancer etiology should be
explored. U.S. population exposure to ionizing radiation,
the major known risk factor for thyroid cancer, has steadily
increased in the past few decades. The National Council on
Radiation Protection and Measurements (NCRP) estimates
that the eﬀective radiation dose to the U.S. population in
2006 was an average of 6.2 milli-Sieverts (mSv) per person
[43]. Most of the average dose per person was from ubiqui-
tous background radiation (3.1mSv) and medical radiation
excluding radiotherapy (3.0mSv). While background radia-
tionincreasedverylittlesince1982,thelastyearforwhichthe
NCRP previously published radiation exposure data for the
U.S. population, the average dose per person from medical
exposure increased from 0.54mSv in 1982 to 3.0mSv in 2006
[43, 44]. This increase was primarily due to increases in the
use of computed tomography (CT, about 1.5mSV average
dose per person in 2006), interventional ﬂuoroscopy, and
nuclear medicine—all relatively high-dose procedures [44],
higher than standard diagnostic X-rays [45]. The number
of CT procedures per year in the USA increased over 10% a
year between 1993 and 2006, from 18.3 million to 62 million
[44].6 Journal of Environmental and Public Health
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Figure 1: (a) Female thyroid cancer incidence rate by age and birth
cohort, New Jersey, 1979–2006, N = 11,215. (b) Male thyroid
cancer incidence rate by age and birth cohort, New Jersey, 1979–
2006, N = 3,772.
As noted by NCRP, not everyone in the USA receives
the average medical radiation dose. Women, elderly, and sick
individuals are more likely to receive higher doses [43, 44],
conﬁrmedbyarecentstudyofexposuretoionizingradiation
from medical imaging procedures received in 2005–2007 by
more than 650,000 adult (18–64 years old) enrollees in a very
large health care organization [46]. The authors estimated
an annual mean eﬀective dose of 2.4 ± 6.0mSv per enrollee
with a wide distribution of dose: 19.4% received >3–20mSv;
1.9% >20–50mSv and 0.2% >50mSv. Women and older
adults had higher eﬀective doses, although 30% of men and
40% of women who received doses greater than 20mSv per
year were between 18 and 49 years of age.
The Board on Radiation Eﬀects Research (BRER),
National Academy of Sciences, recently concluded that the
linear no-threshold risk model applies to low-level ionizing
radiation (including X-radiation and gamma radiation) and
cancer, with the risk of solid cancers in organs rising
proportionately with cumulative exposure [47]. This risk
model predicts that about one of 100 people exposed to
0.1Sv (100mSV) would likely develop a solid cancer or
leukemia. The preferred model of excess relative risk (ERR)
for thyroid cancer is sex-speciﬁc with a factor that doubles
the risk for women compared to men. A recent analysis using
information from the NCRP report [43, 44]a n dB R E Rr i s k
models [47] estimated that about 1,000 thyroid cancers will
result from CT scans performed in 2007 [48].
Although childhood exposure to ionizing radiation has
been considered mainly responsible for increased thyroid
cancer risk due to radiation [4], two recent studies of Ja-
panese atomic bomb survivors found an association between
exposure of adult women to ionizing radiation and thyroid
cancer [49, 50].
Environmental chemicals that have been associated
with disruption of thyroid function and/or with thyroid
cancer—dioxins and polyhalogenated aromatic hydrocar-
bons (e.g., polybrominated diphenyl ethers, polychlorinated
biphenyls)—are suspected to account for some of the
increase in thyroid cancer incidence [9, 16]. Obesity has
been implicated in thyroid cancer etiology, perhaps by
increasing thyroid-stimulating hormones; thus increasing
obesity prevalence in the USA may have contributed to
the rise in thyroid cancer incidence [16, 51]. Changes in
various reproductive and hormonal factors may be partial
explanations for the increase in thyroid cancer incidence
rates, especially since thyroid cancer continues to aﬀect
women much more than men and peaks at an earlier age
in women, but current evidence is weak and inconsistent [4,
51]. Increased dietary iodine intake also has been suggested
as a possible factor in the increasing incidence of thyroid
cancer [15]; however, changes in iodine intake aﬀect speciﬁc
histologic types diﬀerently and the net eﬀect on total thyroid
cancer incidence may be minimal [4].
4.2. Socioeconomic Status (SES) and Health Insurance. The
results of previous research on thyroid cancer and SES, most
using single measures of SES, have been mixed [18–24]. One
recent study examining 1995–2004 thyroid cancer incidence
in Wisconsin counties found a moderate positive correlation
between thyroid cancer incidence and median household
income and percentage of residents with a college degree
[18]. Another study using 1973–2003 data from seventeen
SEER registries found that thyroid cancer patients were more
likely to reside in ZIP codes with higher median income
[19]. Two earlier studies, one of a cohort from a large
health plan in the San Francisco Bay Area [20] and another
using Los Angeles cancer registry data [21], found positive
relationships between thyroid cancer and high educational
attainment [20] and an SES indicator based on U.S. Census
data on household income and education at the census
tract level [21]. Although we used a complex deprivation
index for SES and diﬀerent statistical techniques, our results
were similar—higher SES was associated with higher thyroid
cancer incidence rates.Journal of Environmental and Public Health 7
Table 2
(a) Female thyroid cancer incidence rates by birth cohort, year of diagnosis, and age, New Jersey, 1979–2006, N = 11,215†.
Year of
diagnosis
Age at diagnosis Mid-year of
birth cohort‡
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84
9.0 1899
9.4 8.4 1904
5.8 9.9 8.5 1909
7.7 8.1 9.5 6.4 1914
7.1 10.2 9.2 10.7 11.8 1919
7.8 8.2 10.9 13.3 20.5 18.2 1924
7.7 8.1 10.2 12.3 18.5 30.2 1929
6.8 10.0 10.2 11.4 22.7 29.4 1934
8.5 9.4 10.6 12.5 23.8 30.2 1939
6.6 9.9 11.1 12.9 25.6 29.7 1944
6.6 9.4 9.2 11.7 24.2 34.1 1949
5.1 8.2 9.5 13.8 25.9 36.1 1954
1979–83 4.1 6.7 8.4 13.1 24.5 36.9 1959
1984–88 4.8 8.9 12.1 21.7 27.4 1964
1989–93 5.1 9.3 19.0 29.8 1969
1994–98 6.0 15.7 27.1 1974
1999–03 9.0 19.0 1979
2004–06 10.6 1984
†DataarefromtheNewJerseyStateCancerRegistry,NewJerseyDepartmentofHealthandSeniorServices,November,2008analyticﬁle.Allprimaryinvasive
cases of thyroid cancer diagnosed between 1979 and 2006 are included except death certiﬁcate only and autopsy only cases. Cases 0–19 and 85 or older were
excluded (n = 462). Rates are number of cases per 100,000 population and are not age-adjusted.
‡Birth cohorts are nine-year overlapping groups labeled by the mid-year, for example, the 1899 birth cohort includes people born in 1895–1903.
(b) Male thyroid cancer incidence rates by birth cohort, year of diagnosis, and age, New Jersey, 1979–2006, N = 3,772†.
Year of
diagnosis
Age at diagnosis Mid-year of
birth cohort‡
20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84
5.4 1899
3.9 5.4 1904
3.3 7.7 5.0 1909
6.2 5.5 6.0 6.5 1914
3.4 5.2 6.9 5.6 8.9 1919
4.0 5.7 6.9 7.2 12.8 11.3 1924
2.8 5.4 6.1 7.5 16.0 16.7 1929
2.8 4.4 5.8 8.5 13.0 15.4 1934
2.9 4.7 4.5 6.5 10.0 17.1 1939
2.5 2.9 4.0 5.9 12.1 14.0 1944
2.2 3.5 4.5 5.9 9.1 14.5 1949
1.2 2.0 2.3 3.5 7.1 11.3 1954
1979–83 0.9 1.8 2.1 3.3 6.4 9.4 1959
1984–88 0.9 2.1 3.3 5.3 7.9 1964
1989–93 1.0 2.0 3.3 6.8 1969
1994–98 1.9 3.4 6.1 1974
1999–03 1.8 3.1 1979
2004–06 2.6 1984
†Data are from the New Jersey State Cancer Registry, New Jersey Department of Health and Senior Services, November 2008 analytic ﬁle. All primary invasive
cases of thyroid cancer diagnosed between 1979 and 2006 are included except death certiﬁcate only and autopsy only cases. Cases 0–19 and 85 or older were
excluded (n = 127). Rates are number of cases per 100,000 population and are not age-adjusted.
‡Birth cohorts are nine-year overlapping groups labeled by the mid-year, for example, the 1899 birth cohort includes people born in 1895–1903.8 Journal of Environmental and Public Health
Table 3: Thyroid cancer incidence rates and rate ratios by socioeconomic status (SES) category, New Jersey, 1998–2002, N = 3,924a.
SES
categoryb Total Male Female
Cases Ratec Rate ratiod Cases Ratec Rate ratiod Cases Ratec Rate ratiod
Category 1 1,281 10.6 324 5.5 957 15.4
Category 2 1,185 10.2 1.0 300 5.5 1.0 885 14.7 1.0
Category 3 898 8.3 0.8∗ 225 4.5 0.8∗ 673 12.0 0.8∗
Category 4 560 6.5 0.6∗ 116 3.0 0.5∗ 444 9.7 0.6∗
aData are from the New Jersey State Cancer Registry, New Jersey Department of Health and Senior Services, November 2008 analytic ﬁle. All primary invasive
cases of thyroid cancer diagnosed between 1998 and 2002 are included except cases identiﬁed only through death certiﬁcates or autopsy reports and cases not
geocoded to a census tract (n = 51).
bCensus tracts were grouped into SES quartiles using the deprivation index scores. The deprivation index was developed with New Jersey 2000 U.S. Census
data using principle component analysis. Census tract deprivation index scores in Category 1 were –2.23 to –0.71, in Category 2 were –0.72 to –0.14, in
Category 3 were –0.13 to 0.59, and in Category 4 were 0.60 to 0.32. Category 1 is the highest SES category and Category 4 the lowest SES category.
cRates are age-adjusted to the 2000 U.S. Standard Population, direct method, and are expressed as the number of cases per 100,000 population.
dThe rate ratio is the rate for this SES category divided by the rate for SES Category 1 (referent rate).
∗The rate for this SES category is signiﬁcantly lower than the rate for SES Category 1, P<0.05.
A case-control study of Southeast Asian women living
in the San Francisco Bay Area found that lower educational
attainment was associated with an increased risk of thyroid
cancer [22] and two case-control studies from the 1980s,
in Hawaii [23] and Connecticut [24], found no association
between thyroid cancer and education or occupation. These
contradictory results suggest that the positive relationship
between SES and thyroid cancer may be reversed for certain
populations, for example, Asian and Paciﬁc Islanders, and
may be a more recent occurrence.
The authors of the Wisconsin and Los Angeles cancer
registry studies noted that the positive association between
thyroid cancer and SES may be due to increased diagnosis
due to better access to health care in higher SES groups
[18, 21]. However, in the San Francisco cohort study, the
positiveassociationofthyroidcancerwithahigheducational
level was not believed to be due to detection bias as everyone
in the cohort had equal access to health care [20].
The Wisconsin county study found a strong positive
correlation between thyroid cancer incidence and percent of
residents covered by health insurance [18], and the SEER
study found positive correlations between state and zip
code level health insurance status and thyroid cancer [19].
The Pearson correlation coeﬃcients in these two studies
were similar to ours, r = 0.41 and 0.56, respectively. This
correlation is consistent with the ﬁndings of a positive
association between high SES and thyroid cancer, as persons
of higher SES are more likely to have health insurance [52].
The results of our study and others showing a positive
association between thyroid cancer and high SES and health
insurance coverage also are consistent with the hypothesis
that increased exposure to medical (including diagnostic)
ionizing radiation explains part of the rise in thyroid cancer.
In conclusion, thyroid cancer incidence increased greatly
in NJ between 1979 and 2006, especially since 1997, with no
indication of stabilizing. Our time trend, birth cohort, and
SESresultssupportfurtherinvestigationintotherelationship
between rising thyroid cancer incidence and increasing pop-
ulationexposuretomedical(includingdiagnostic)radiation,
as well as widespread use ofmore sensitive diagnostic tech-
niques. In the meantime, measures to encourage appropriate
use of medical radiation would be prudent.
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